quanterix offers an ultra-sensitive diagnostic platform capable of measuring individual proteins at concentrations 1000 times lower than the best immunoassays available today. the single molecule array (simoa™) technology at the heart of the platform enables the detection and quantification of biomarkers previously difficult or impossible to measure, opening up new applications to address significant unmet needs in life science research, in-vitro diagnostics, companion diagnostics, blood screening, and more. quanterix is a venture capital backed company and the exclusive licensee of a broad intellectual property portfolio initially developed at tufts university by dr. david walt, scientific founder of quanterix and illumina (nasdaq: ilmn).
Company profile
Ticker
QTRX
Exchange
Website
CEO
E. Kevin Hrusovsky
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Aushon Biosystems, Inc. • Quanterix Security Corporation • Quanterix Netherlands B.V. • UmanDiagnostics AB • Quanterix Holdings • Quanterix Bio-tech (Shanghai) Co., Ltd ...
QTRX stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
15 Apr 24
DEFA14A
Additional proxy soliciting materials
15 Apr 24
DEF 14A
Definitive proxy
15 Apr 24
8-K
Departure of Directors or Certain Officers
12 Apr 24
S-8
Registration of securities for employees
4 Mar 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
Quanterix Releases Operating Results for Fourth Quarter and Full Year 2023
29 Feb 24
8-K
Quanterix Reschedules Q4 and Full Year 2023 Earnings Conference Call; Reaffirms 2023 Guidance
26 Feb 24
8-K
Departure of Directors or Certain Officers
30 Jan 24
8-K
Results of Operations and Financial Condition
10 Jan 24
Transcripts
QTRX
Earnings call transcript
2023 Q3
7 Nov 23
QTRX
Earnings call transcript
2023 Q2
8 Aug 23
QTRX
Earnings call transcript
2023 Q1
9 May 23
QTRX
Earnings call transcript
2022 Q4
6 Mar 23
QTRX
Earnings call transcript
2022 Q4
3 Mar 23
QTRX
Earnings call transcript
2022 Q3
9 Nov 22
QTRX
Earnings call transcript
2022 Q2
9 Aug 22
QTRX
Earnings call transcript
2022 Q1
10 May 22
QTRX
Earnings call transcript
2021 Q4
1 Mar 22
QTRX
Earnings call transcript
2021 Q3
7 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 203.91 mm | 203.91 mm | 203.91 mm | 203.91 mm | 203.91 mm | 203.91 mm |
Cash burn (monthly) | 42.77 mm | 11.87 mm | 4.59 mm | 4.56 mm | 1.35 mm | 1.42 mm |
Cash used (since last report) | 291.81 mm | 80.99 mm | 31.32 mm | 31.11 mm | 9.21 mm | 9.67 mm |
Cash remaining | -87.91 mm | 122.92 mm | 172.59 mm | 172.80 mm | 194.70 mm | 194.24 mm |
Runway (months of cash) | -2.1 | 10.4 | 37.6 | 37.9 | 144.3 | 137.0 |
Institutional ownership, Q3 2023
92.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 162 |
Opened positions | 30 |
Closed positions | 7 |
Increased positions | 56 |
Reduced positions | 50 |
13F shares | Current |
---|---|
Total value | 868.06 bn |
Total shares | 35.49 mm |
Total puts | 115.20 k |
Total calls | 96.80 k |
Total put/call ratio | 1.2 |
Largest owners | Shares | Value |
---|---|---|
Arch Venture Fund Vi | 3.12 mm | $145.09 mm |
BLK Blackrock | 2.92 mm | $79.31 bn |
Vanguard | 2.00 mm | $54.21 bn |
Millennium Management | 1.98 mm | $53.73 bn |
Portolan Capital Management | 1.68 mm | $45.48 bn |
Camber Capital Management | 1.28 mm | $34.60 bn |
Gilder Gagnon Howe & Co | 1.23 mm | $33.28 bn |
IVZ Invesco | 1.10 mm | $29.96 bn |
Lord, Abbett & Co. | 1.02 mm | $27.74 bn |
Pura Vida Investments | 961.24 k | $26.09 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Apr 24 | Masoud Toloue | Common Stock | Payment of exercise | Dispose F | No | No | 17.15 | 1,120 | 19.21 k | 341,318 |
1 Apr 24 | Laurie J Olson | Common Stock | Sell | Dispose S | No | Yes | 23.5 | 1,000 | 23.50 k | 15,238 |
1 Apr 24 | Laurie J Olson | Common Stock | Option exercise | Acquire M | No | No | 12.86 | 1,000 | 12.86 k | 16,238 |
1 Apr 24 | Laurie J Olson | Stock Option Common Stock | Option exercise | Dispose M | No | No | 12.86 | 1,000 | 12.86 k | 10,124 |
1 Apr 24 | Donnelly William P | Common Stock | Grant | Acquire A | No | No | 23.78 | 525 | 12.48 k | 32,598 |
1 Apr 24 | Meister Paul M | Common Stock | Grant | Acquire A | No | No | 23.78 | 630 | 14.98 k | 293,347 |
1 Apr 24 | Hlavinka Sarah E. | Common Stock | Grant | Acquire A | No | No | 23.78 | 630 | 14.98 k | 43,619 |
News
Quanterix Reveals Specific Partnership Path For Laboratories Interested In Offering Tau Based Research And Diagnostic Testing Services
21 Mar 24
Scotiabank Maintains Sector Outperform on Quanterix, Raises Price Target to $32
4 Mar 24
Quanterix Granted Breakthrough Device Designation From U.S. FDA For Blood-Based p-Tau 217 Test For Alzheimer's Disease
4 Mar 24
Earnings Scheduled For February 29, 2024
29 Feb 24
Earnings Preview: Quanterix
28 Feb 24
Press releases
Quanterix Outlines Partner Path With Labs to Expedite Building Global Alzheimer's Disease Testing Infrastructure
21 Mar 24
Quanterix Granted Breakthrough Device Designation from U.S. FDA for Blood-Based p-Tau 217 Test for Alzheimer's Disease
4 Mar 24
Quanterix Releases Operating Results for Fourth Quarter and Full Year 2023
29 Feb 24
Quanterix Reschedules Q4 and Full Year 2023 Earnings Conference Call; Reaffirms 2023 Guidance
26 Feb 24
Quanterix to Present at Cowen's 44th Annual Health Care Conference
23 Feb 24